Tianjin Cancer Hospital has proposed a new standard for breast cancer diagnosis, which has reduced the local recurrence rate of breast invasive micropapillary carcinoma from 11.2% to 1.27%, and the 3-year survival rate from 59% to 100%.
This major advancement in medical technology comes from the research project on the biological behavior and application of breast invasive micropapillary carcinoma, which was completed by the research team led by Professor Fu Li, a breast pathologist in Tianjin Cancer Hospital. This research won the second prize of the China Medical Science and Technology Award.
About 1.2 million new breast cancers are found every year in the world, and about 500,000 people die of breast cancer every year. Because the same patient's cancer tissue may contain several different tissue types, and each type has different biological characteristics, the clinical treatment plan is not the same. However, if the breast cancer patient's diseased tissue contains invasive micropapillary carcinoma, it means that the disease is much more serious than ordinary breast cancer patients. For the invasive micropapillary carcinoma in the tumor can be diagnosed as this type of tumor, there is no uniform diagnostic criteria in the medical community, resulting in some breast cancer patients are misdiagnosed or missed.
Professor Fu Li led the research team to apply the new sectioning technique to analyze the relationship between the proportion of invasive micropapillary carcinoma in cancer tissues and biological behavior, and to explore the diagnostic criteria. The results show that the invasive and metastatic rate of invasive micropapillary carcinoma is extremely high, and a small proportion of invasive micropapillary carcinoma can seriously affect the prognosis of patients. In view of this, the research team* proposed a convincing diagnostic criterion for Zui, that is, as long as invasive micropapillary cancer components appear in cancer tissues, the diagnosis should be clearly made and the proportion should be indicated, so that the invasive micropapills Patients with cancer are exempt from missed diagnosis.
This major advancement in medical technology comes from the research project on the biological behavior and application of breast invasive micropapillary carcinoma, which was completed by the research team led by Professor Fu Li, a breast pathologist in Tianjin Cancer Hospital. This research won the second prize of the China Medical Science and Technology Award.
About 1.2 million new breast cancers are found every year in the world, and about 500,000 people die of breast cancer every year. Because the same patient's cancer tissue may contain several different tissue types, and each type has different biological characteristics, the clinical treatment plan is not the same. However, if the breast cancer patient's diseased tissue contains invasive micropapillary carcinoma, it means that the disease is much more serious than ordinary breast cancer patients. For the invasive micropapillary carcinoma in the tumor can be diagnosed as this type of tumor, there is no uniform diagnostic criteria in the medical community, resulting in some breast cancer patients are misdiagnosed or missed.
Professor Fu Li led the research team to apply the new sectioning technique to analyze the relationship between the proportion of invasive micropapillary carcinoma in cancer tissues and biological behavior, and to explore the diagnostic criteria. The results show that the invasive and metastatic rate of invasive micropapillary carcinoma is extremely high, and a small proportion of invasive micropapillary carcinoma can seriously affect the prognosis of patients. In view of this, the research team* proposed a convincing diagnostic criterion for Zui, that is, as long as invasive micropapillary cancer components appear in cancer tissues, the diagnosis should be clearly made and the proportion should be indicated, so that the invasive micropapills Patients with cancer are exempt from missed diagnosis.
We are China ningxia middle seed producer, we provide quality of Cucumber seeds, green skin cream Melon Seeds, we produce seeds of cucumber seeds are clean, facilities, outdoor cultivation, good shelf quality, disease resistance is stronger, cucumber is up to 3500 kg per mu, milk melon of up to 3000 kg per mu.
Cucumber seeds
Cucumber Seed,Green Skin Milk Melon Seeds,Early Maturity Vegetable Cucumber Seed,Hybrid Little Cucumber Seeds
Ningxia Zhongqing Agricultural Technology Co. Ltd. , https://www.zq-vegetableseeds.com